采用基因配型行同种异体肾移植术

目的 探讨基因配型技术在同种异体肾移植中的应用。方法采用顺序特异引物聚合酶链反应法(PCR-SSP)分别进行供、受体的基因分型，为3例配型适当的终末性肾病患者行同种异体肾移植术，并观察其术后肾功能恢复情况。结果所有接受肾移植的患者于术后2d肾功能恢复至正常水平，无急性和超急性排异发生。随访11-15个月，各项检查指标均正常。结论 基因配型的准确率较之传统的血清学配型显著增加，显著提高同种异体肾移植的成功率。     

窒息新生儿肾功能损害

对50例窒息新生儿肾功能检测结果发现：19例（38％）血清肌酐浓度升高，23例（46％）血。α_1－M升高，24例（48％）尿。α_1－M升高，29例（58％）尿NAG指数升高；7例（14％）发生急性肾功能衰竭。提示窒息新生儿常合并肾功能损害，尿NAG检测可作为监测窒息新生儿肾功能常规检查方法之一。     

代谢综合征患者肾动脉狭窄的SCTA与DSA对比研究

目的探讨代谢综合征(MS)患者中肾动脉狭窄的发生率及无创性筛检的必要性与可靠性。方法45例MS患者预行肾动脉螺旋CT血管造影(SCTA),对所检出的14例肾动脉狭窄者行肾动脉数字减影血管造影(DSA)对照,并对SCTA及DSA结果进行对比分析。结果45例MS患者中SCTA显示肾动脉正常31例,其余14例患者存在单侧或双侧肾动脉狭窄,DSA对照显示肾动脉正常6条,肾动脉狭窄22条,与SCTA显示的情况基本符合。结论MS患者中肾动脉狭窄的发生率约31.1%,对可疑患者应常规予以肾动脉SCTA检查。     

阻塞性睡眠呼吸暂停综合征患者肾功能和心钠素的变化分析

目的探讨病人肾功能、心钠素(ANP)的含量变化及经鼻持续气道正压(nCPAP)治疗对阻塞性睡眠呼吸暂停综合征(OSAS)患者的影响。方法选择经多导睡眠图(PSG)确诊为中、重度的OSAS患者11例为试验组,PSG检查正常者14例为对照组，试验组给予nCPAP治疗，分别测定其血尿肌酐、尿量、尿β2-微球蛋白(β2-MG)、血浆心钠素(ANP)，并计算出内生肌酐清除率(Ccr)，比较试验组与对照组及试验组治疗前后各项指标的差异。结果试验组与对照组比较，Ccr,尿β2-MG差异无显著性，经nCPAP治疗后两指标也无明显改变；试验组的夜尿量、血ANP含量显著高于对照组，nCPAP治疗后上述指标均较治疗前明显下降。结论OSAS患者夜尿量增多可能与ANP增加有关，这种增高可以被nCPAP治疗所纠正。     

不同剂量环孢素A对肾移植病人精液质量的影响

目的 :探讨不同治疗剂量环孢素A(CsA)对肾移植病人精液主要参数和精子形态学的影响。　方法 :对 18例应用不同治疗剂量CsA的肾移植病人的精液进行主要参数和精子形态学分析 ,并与 12例正常男性精液进行比较。　结果 :CsA剂量在 1.5～ 3.0mg·Kg-1·d-1及 3.1～ 5 .5mg·Kg-1·d-1时 ,病人精液的主要参数与正常男性精液比较差异无显著性 (P >0 .0 5 ) ,但病人正常形态精子百分率与正常男性相比差异有显著性 (P <0 .0 5 )。结论 :不同治疗剂量的CsA对肾移植病人的精液主要参数无明显影响 ,但对精子形态可能有一定的影响。     

Tubulointerstitial nephritis caused by the antiviral agent foscarnet

The antiviral agent foscarnet has long been used in our unit to treat cytomegalovirus (CMV) infections in renal transplant patients. The clinical effect has been convincing and, apart from changes in serum calcium levels, very few side effects have been noted. We have, however, observed a nephrotoxic reaction in a series of patients with initially good renal function who therefore received high doses of foscarnet. Transplant biopsies performed in five of those patients revealed degenerative changes in the tubular epithelial cells as well as tubular calcium deposits and an infiltration of the interstitium by mixed mononuclear and polymorphonuclear leucocytes. Renal insufficiency was accompanied by high fever. After withdrawal of the drug, the temperature rapidly normalized, whereas serum creatinine continued to rise for about 3 days and then fell back towards previous levels. We conclude that transplant biopsies are of great value in distinguishing between a foscarnet nephrotoxic effect and CMV nephritis, various forms of rejection, and other causes of impaired renal function.     

Hypertension following renal transplantation in children

The files of 334 consecutive cadaver kidney (CK) and of 27 living related (LR) transplantations (T) in children and adolescents performed from 1973 to 1984 have been reviewed. Following cadaver transplantation, 52 patients (15%) never had hypertension (HT), 41 patients (12%) had only initial HT up to 6 months after transplantation and 18 other patients (5%) exhibited transient HT episodes while on high-dose steroid therapy. Finally, 209 patients (62%) had HT for periods longer than 6 months and 16 patients (5%) until death or graft failure within the first 3 months. Chronic graft rejection was the major cause of HT, but other factors either isolated or in association were also present. Renal artery stenosis (RAS) was diagnosed in 43 cases (13%) 2–17 months post-transplantation; 10 of these were operated upon (5 successfully) and 9 underwent transluminal angioplasty with a single success. Nine cases of RAS resolved spontaneously. HT was attributed to the host kidney in 10 cases (3%) and to recurrence of primary renal disease in 9 (3%). HT observed after CKT was sometimes severe and difficult to control. Acute complications from HT were recorded in 35 cases, with 6 deaths and 2 severe neurological sequelae. Among 25 LRT, 11 cases (40%) had no HT 13 (48%) had HT for longer than 6 months. In this group, no case of RAS was observed and only one complication (without sequelae) was noted. In conclusion, HT is a frequent and sometimes severe complication post-transplantation in children and adolescents.     

Effect of cirrhosis and renal failure on the kinetics of clotiazepam

Summary The kinetics of a single 5-mg oral dose of the thienodiazepine clotiazepam was evaluated in a series of patients with biopsy-proven cirrhosis, and in patients with renal insufficiency requiring maintenance hemodialysis, compared to healthy matched controls. Clotiazepam volume of distribution (V_z) was significantly smaller in cirrhotic patients than in controls (1.83 vs 2.57 l/kg), and total clearance was likewise reduced (2.15 vs 3.15 ml/min/kg). Elimination half-life was similar between groups (10.0 vs. 10.2h). There were no significant differences between renal failure and control patients in clotiazepam V_z, oral clearance, or elimination half-life. Thus cirrhosis is associated with reduced clearance of clotiazepam, probably due to impairment of its microsomal oxidation. However clotiazepam disposition is not significantly altered in dialysis-dependent renal insufficiency patients.Supported in part by Grant OC 10/6–4 from Deutsche Forschungsgemeinschaft, and Grant MH-34223 from the United States Public Health Service.     

慢性肾功能不全患者行冠状动脉搭桥术围术期处理

目的：探讨慢性肾功能不全患行冠状动脉搭桥术的安全性。方法：回顾性分析1996年6月至2001年6月收治的15例慢性肾功能不全患行冠状动脉搭桥术的临床资料，并复习献。结果：9例患术后早期肾功能指标较术前差；6例患术后早期肾功能技术前无明显变化。围术期腹透4例，血透2例，其中1例行术中血透，肾功能指标均有所改善。全组无术中死亡，1例枚后第三天死于多器官功能衰竭。结论：术前肾功能不全的患，经过积极的术中及围术期处理，大多可以安全渡过肾功能衰竭关，接受冠状动脉搭桥术，达到改善症状延长生命的目的。     

Effect of prostaglandin E1 on graft function of kidneys from living related donors

Prostaglandin E₁ (PGE₁) was used in renal transplant recipients with living related donors. The drug was given intravenously from day 1 to day 7 after transplantation at a dose of 40 µg/kg twice a day. A total of 45 patients were studied divided into two groups: 25 patients were treated with PGE₁ (group B) and the remaining 20 patients did not receive the drug (group A). In group B, 24-h creatinine clearance (Ccr) was 66 ± 12.8 ml/min compared with 40.3 ± 13.4 ml/min in group A on the fifth postoperative day (P < 0.05). Urinary levels of N-acetyl-β-d -glucosaminidase (NAG) and serum levels of platelet factor 4 (PF4) in group B were significantly lower than in group A. On the fourth postoperative day, the urinary excretion of thromboxan B₂ (TxB₂) in group A was higher than in group B, but not significantly (5.1 ± 3.0 ng/day and 2.8 ± 1.1 ng/day, respectively). Acute rejection occurred in four patients in group B and in 10 patients (40%) in group A. The percentage of Leu2a-positive lymphocytes in group B was higher than in group A. We conclude that postoperative administration of PGE₁ improves graft function in kidneys from living related donors.